Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.
Phillippe Gabriel StegDeepak L BhattStefan K JamesOliver DarlingtonLouise HoskinTabassome SimonKim M FoxLawrence A LeiterShamir R MehtaRobert A HarringtonAnders HimmelmannWilhelm RidderstråleMarielle AnderssonHéctor BuenoLeonardo De LucaAmarjeet TankCarl MellströmPhil McEwanPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Based on THEMIS results, ticagrelor plus aspirin compared with aspirin alone may be cost-effective in some European countries in patients with T2DM and CAD and no prior myocardial infarction (MI) or stroke. Additionally, ticagrelor is likely to be cost-effective across European countries in patients with a history of PCI.
Keyphrases
- percutaneous coronary intervention
- antiplatelet therapy
- coronary artery disease
- acute coronary syndrome
- cardiovascular events
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery bypass grafting
- atrial fibrillation
- low dose
- coronary artery bypass
- heart failure
- clinical trial
- phase iii
- study protocol
- left ventricular
- weight loss
- skeletal muscle
- adipose tissue
- brain injury